Drugs / ORVACABTAGENE AUTOLEUCEL
ORVACABTAGENE AUTOLEUCEL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03430011 | Feb 2018 → Mar 2023 | plasma cell myeloma | Juno Therapeutics, a Subsidiary of Celgene | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORVACABTAGENE AUTOLEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594309 ↗ |
| Known as | JCARH125 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430011 ↗ |
| Known as | Orvacabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594309 ↗ |
| Modality | Cell therapy | “JCARH125, a CAR T-cell product” NCT03430011 ↗ |
| Route | Intravenous | “JCARH125 administered intravenously (IV)” NCT03430011 ↗ |